A comparative study on metabolic syndrome in patients with schizophrenia treated using first-generation and second-generation antipsychotics

Modulation of Leucine Sensors to Mitigate Antipsychotics-Induced Metabolic Syndrome: A New Vista

“…Second-generation antipsychotics (SGAs) effectively control symptoms associated with a wide array of psychiatric disorders, including schizophrenia and bipolar disorder . However, they are notorious for inducing metabolic syndrome, a constellation of symptoms ranging from cardiovascular problems, dyslipidemia, weight gain, and glucose dysregulation. , Metabolic syndrome is a known factor playing a role in shorter life expectancy and premature death, primarily due to cardiovascular mortalities . The rate of the incidence of metabolic syndrome varies among different antipsychotics, having olanzapine and clozapine with the highest likelihood, followed by quetiapine, risperidone, and paliperidone. , To top it off, the rate of diabetes, cardiovascular disorders, and atherogenic dyslipidemia are 3- to 5-fold greater in patients with schizophrenia than in the general population, and virtually one-third of patients with schizophrenia exhibit metabolic abnormalities with an incidence of almost 70% in patients with chronic schizophrenia. , …”

“…4 The rate of the incidence of metabolic syndrome varies among different antipsychotics, having olanzapine and clozapine with the highest likelihood, followed by quetiapine, risperidone, and paliperidone. 2,3 To top it off, the rate of diabetes, cardiovascular disorders, and atherogenic dyslipidemia are 3-to 5-fold greater in patients with schizophrenia than in the general population, and virtually one-third of patients with schizophrenia exhibit metabolic abnormalities with an incidence of almost 70% in patients with chronic schizophrenia. 3,4 SGAs are efficacious and benefit from a low risk of extrapyramidal side effects; therefore, despite carrying adverse metabolic profiles they are still the mainstay and first-line treatment options for many psychiatric illnesses when administered at clinically therapeutic doses.…”

“…1 However, they are notorious for inducing metabolic syndrome, a constellation of symptoms ranging from cardiovascular problems, dyslipidemia, weight gain, and glucose dysregulation. 2,3 Metabolic syndrome is a known factor playing a role in shorter life expectancy and premature death, primarily due to cardiovascular mortalities. 4 The rate of the incidence of metabolic syndrome varies among different antipsychotics, having olanzapine and clozapine with the highest likelihood, followed by quetiapine, risperidone, and paliperidone.…”

Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report

“…Atypical antipsychotics lead weight gain, increase insulin resistance, and lipid abnormalities 6 . Some study, highlight that prevalence of metabolic syndrome in schizophrenia patients treated with atypical antipsychotics (20.40%) higher than in schizophrenia patients treated with typical antipsychotics (9.18%) 7 .…”